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OBJECTIVES: Sarcopenia is a common treatable geriatric condition. The aim of this study was to estimate the
prevalence of sarcopenia and its associated factors in community-dwelling elderly living in Rio de Janeiro, Brazil,
and to discuss the impact of different muscle mass, handgrip strength and gait speed cut-off values on the
reported frequency of sarcopenia.
METHODS: The health habits, functional capacity, and anthropometric measurements of 745 individuals aged
X65 years from the Frailty in Brazilian Older People study were analyzed. The participants were classified into
the following four groups: no sarcopenia, pre-sarcopenia, sarcopenia and severe sarcopenia. Univariate and
multivariate regression analyses were performed. Muscle mass, handgrip strength and gait speed cut-off
thresholds tailored to the sample and those proposed by the European Working Group on Sarcopenia in Older
People were used to compare the prevalence rates of sarcopenia.
RESULTS: Seventy-three percent of the participants were female, 61.9% were Caucasian, and the mean age was
76.6 years. The prevalence rates of sarcopenia were 10.8% and 18% using the sample-tailored and European
consensus cut-off values, respectively. Sarcopenia was associated with advanced age (OR: 37.2; CI95%12.35-
112.48), Caucasian race (OR: 1.89; CI 95% 1.02-3.52), single marital status (OR:6; CI95% 2.2-16.39), low income
(OR:3.64; CI 95% 1.58-8.39), and the presence of comorbidities (OR:3.26; CI 95%1.28-8.3).
CONCLUSION: In this study, the estimated prevalence of sarcopenia was similar to that reported in most studies
after the tailored handgrip strength and gait speed cut-off values were adopted. A higher prevalence was
observed when the cut-off values suggested by the European consensus were used. This indicates that the
prevalence of sarcopenia must be estimated using population-specific reference values.
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’ INTRODUCTION
In Brazil, epidemiological and demographic changes mean
that 650,000 elderly people appear in the population each
year. Most have multiple chronic morbidities, and a con-
siderable number have cognitive impairments and functional
limitations (1). The increase in life expectancy has become a
primary risk factor for morbidity and disability, displacing
morbidity and mortality risks from younger to older groups.
As a consequence, the entire society will become tasked
with the care of a greater proportion of people with chronic
diseases (2).
Included among the most important diseases affecting
elderly people is sarcopenia. This is a geriatric condition
ascribed to the ageing process; however, it can be treated and
even cured (3). Muscle mass (MM) represents approximately
45% of the composition of the body. It is estimated that
healthy individuals lose approximately 1% of their MM per
year after the age of 30 years. For this reason, some authors
consider the loss of MM to be the most dramatic and
functionally significant change associated with ageing (4).
Many published studies have indicated a drastic reduction in
the quality of life and the prognosis of elderly people with
sarcopenia compared to those without it (5). Patients with
sarcopenia display disordered muscle tissue and metabolism.
The cellular processes underlying the development and pro-
gression of sarcopenia cause negative outcomes by decreasing
an individual’s strength, mobility, and functional capacity (6).
Sarcopenia is directly associated with functional depen-
dency, institutionalization, lengthier hospital stays, higher
numbers of hospitalizations, higher mortality rates and
higher healthcare-related costs. Nevertheless, sarcopenia
does not have a well-established conceptual or operational
definition (7). Its former operational definition was entirelyDOI: 10.6061/clinics/2019/e477
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based on MM (8,9). Recently, there has been evidence
suggesting the need to expand this definition to include
the measurement of muscle quality in addition to muscle
quantity (10).
In the last few years, with the aim of consolidating the new
evidence, several agencies and researchers have collaborated
to develop criteria for the screening, diagnosis, and treatment
of sarcopenia (11). To accomplish this, investigators proposed
several tools and biomarkers for assessing sarcopenia.
However, many of these protocols are dependent on the
clinical context and on the cut-off values for items used to
identify vulnerable individuals in each examined population
(12). The use of various diagnostic criteria for sarcopenia has
returned a range of prevalence rates spanning from 2 to 34%
in epidemiological studies (13).
Early diagnosis and intervention are extremely important to
arrest the disability cascade that accompanies a clinical con-
dition with this potential prevalence and well-known negative
outcomes. The aims of this study were to estimate the pre-
valence of sarcopenia based on MM, strength, and function-
ality and to analyze the relationships between sarcopenia
and sociodemographic factors, functional ability, and health
status in a sample of community-dwelling individuals living
in Rio de Janeiro, Brazil. We also aimed to evaluate the impact
of various MM, handgrip strength (HS) and gait speed (GS)
cut-off values on the reported prevalence of sarcopenia.
’ MATERIALS AND METHODS
This study was a cross-sectional analysis of the baseline
data of the Frailty in Brazilian Older People study, Rio de
Janeiro, Brazil (Fibra-RJ). The Fibra-RJ methodology is des-
cribed elsewhere (14). Briefly, a longitudinal study evaluated
745 elderly (65 years and older) members of private health
insurance plans living in northern Rio de Janeiro, Brazil. The
study was conducted through home interviews, from January
2009 to January 2010 and assessed sociodemographic data,
health habits, functional abilities, self-reported comorbidities,
levels of physical activity, and cognition variables.
Sarcopenia was diagnosed and classified using the consen-
sus diagnostic criteria proposed by the European Working
Group on Sarcopenia in Older People (EWGSOP) (11).
The four strata based on MM, HS and GS were as follows:
pre-sarcopenia = low MM only, sarcopenia = low MM plus
low HS or GS, severe sarcopenia = low MM plus low HS and
GS, and normal = none of the aforementioned conditions.
To compare the impacts of different HS and GS cut-off
values on sarcopenia incidence rates, two different appro-
aches were used. First, the cut-off values were tailored to the
sample. The individuals were considered weak or slow if
they were in the first quintile in terms of MM, HS, and GS;
second, the cut-off values were determined to be MM o5.45
kg/m2 and o7.26 kg/m2(8) for women and men, respec-
tively; HS o20 kgf and 30 kgf for women and men, res-
pectively; and GS o0.8 m/s for both sexes (11).
A dynamometer (JAMAR-J00105) was used to assess HS,
which was tested with three repetitions in the dominant
hand. The average of these three measures, adjusted for sex
and body mass index, was used to determine muscle strength.
Functional performance was measured by GS using a chro-
nometer to calculate the time required to walk 4.6 metres,
adjusted for height and sex (15). In both approaches, MM was
estimated using a formula proposed by Lee et al. (16) that
evaluates total skeletal MM based on body weight, height,
age, sex, and race. Individuals in the first quintile were con-
sidered to have low MM (Table 4) (15,17,18).
Ethics approval
This study was funded by a grant from the National
Research Council - Brazil (Conselho Nacional de Pesquisa -
CNPq) and the Carlos Chagas Filho Foundation for Research
Support of the State of Rio de Janeiro, Brazil (Fundac¸ão
Carlos Chagas de Apoio à Pesquisa - FAPERJ). All subjects
signed a consent form. The ethics committee of Hospital
Universitário Pedro Ernesto approved the study.
Statistical analysis
To describe the sample and to compare the prevalence rates
of sarcopenia calculated by the various strategies, contingency
tables were created and the Chi-square and Somer tests were
used. For the multivariate regression, the sample was divided
into the following two groups: sarcopenic and not sarcopenic;
the pre-sarcopenic individuals were excluded from this ana-
lysis. Each variable with statistical significance in the univariate
analysis (po0.2) was included in the multivariate model.
Severe sarcopenia and sarcopenia were considered to be one
group because severe sarcopenia was underrepresented in the
sample. The Hosmer-Lemeshow test was used to analyze the
discriminatory ability of the model. All descriptive statistics
were calculated assuming a 95% confidence interval (CI) and a
significance level of 0.05. Analyses were performed using SPSS,
version 23, IBM Software, 2015, Chicago.
’ RESULTS
A brief report on the findings of the present study was
presented in the poster session of the XXI World Congress of
Gerontology and Geriatrics (19).
Of the 745 observed individuals (mean age 76.6±6.9
years), 70.3% were women, 61.9% were Caucasian, and
42.8% were married or living with a partner. Most had more
than 6 years of education (73.6%) and an income greater than
2.1 times the minimum wage (83.1%). Of these individuals,
52.8% were dependent for instrumental activities of daily
living (IADL), and 18.5% were dependent for basic activities
of daily living. A large proportion of the sample (56.2%)
reported their own health as good or very good, and 71.8%
reported no falls during the previous year (Table 1).
Hypertension and osteoarthritis were the most prevalent
conditions (64.7% and 35.9%, respectively).
Table 2 displays the cut-off points tailored for this sample.
The prevalence of sarcopenia according to the tailored cut-off
values and the EWGSOP criteria are presented in Table 3.
According to the consensus guidelines of the EWGSOP, the
cut-off points for MM were 7.26 and 5.45 kg/m2 for men and
women, respectively. The cut-off points for HS were 30 kgf
for men and 20 kgf for women, and for GS, the cut-off values
was 0.8 m/s for both sexes.
In the univariate regression model, race, age group,
marital status, education level, income, comorbidities, and
IADL were associated with sarcopenia. In the multivariate
model, IADL did not maintain an association (Table 4). The
distribution of MM, HS, and GS using the tailored cut-off
values is shown in Figure 1.
’ DISCUSSION
In this study, sarcopenia had an estimated prevalence of
10.8% (sarcopenia and severe sarcopenia). The prevalence of
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sarcopenia was associated with advanced age, Caucasian
race, reduced social support, illiteracy, low income, and the
presence of comorbidities. Other studies that used the same
approaches reported similar results (13,20). Nevertheless,
when the cut-off points suggested by the EWGSOP were
adopted, the prevalence of sarcopenia increased more than
7% of the actual value.
Reduced MM, strength, and functionality have been
associated with adverse outcomes and mortality in patients
with sarcopenia (21). The EWGSOP has proposed these
factors as standards for detecting sarcopenia, and in the last 5
years, they have become the most commonly used criteria for
diagnosing sarcopenia worldwide (11). Nevertheless, there
are some issues associated with this operational definition.
Table 2 - Sample tailored cut-off values for handgrip strength, gait speed and muscle mass among community-dwelling individuals
aged 65 years or older who are residents of the northern region of Rio de Janeiro, Brazil, 2010. (n=745).
Cut-off values by gender
Men Women
BMIa Handgrip strength (kgf) BMI Handgrip strength (kgf)
Muscle strengthb p22.40 16.8 p24.12 13.3
22.40o to p25.51 23.3 24.12o to p26.92 14.0
25.51o to p28.33 23.3 26.92o to p30.26 14.0
428. 33 23.4 430.26 14.7
Height (m) Gait speed (m/s) Height (m) Gait speed (m/s)
Physical performancec p1.68 o0.65 p1.54 o0.60
41.68 o0.73 41.54 o0.69
Muscle massd 8.83 6.64
a BMI - Body Mass Index;
bMuscle strength estimated through handgrip strength using the Body Mass Index quartile and the sex-specific lowest quintile;
c Physical performance estimated through gait speed using the usual pace for 4.6 meters, median height and sex-specific lowest quintile;
dMuscle mass estimated through anthropometric measurement with sex-specific lowest quintile (kg/m2).
Table 1 - Sociodemographic characteristics, health statuses and comorbidities in community-dwelling individuals aged 65 years or
older who are residents of the northern region of Rio de Janeiro, Brazil, 2010. Fibra-RJ study. (n=745)
No sarcopenia Pre-sarcopenia Sarcopenia Total
n (%) n (%) n (%) n (%)
Sex Female 423 (70.5) 39 (60) 62 (77.5) 524 (70.3)
Male 177 (29.5) 26 (40) 18 (22.5) 221 (29.7)
Race Other 245 (40.8) 16 (24.6) 23 (28.8) 284 (38.1)
Caucasian 355 (59.2) 49 (75.4) 57 (71.3) 461 (61.9)
Age (years) 65 – 74 304 (50.7) 11 (16.9) 5 (6.3) 320 (43.0)
75 – 84 245 (40.8) 45 (69.2) 39 (48.8) 329 (44.2)
485 51 (8.5) 9 (13.8) 36 (45) 96 (12.9)
Marital status Married/living with partner 278 (46.3) 25 (38.5) 16 (20) 319 (42.8)
Divorced/separated 49 (8.2) 3 (4.6) 6 (7.5) 58 (7.8)
Single 58 (9.7) 11 (16.9) 13 (16.3) 82 (11)
Widower 215 (35.8) 26 (40) 45 (56.3) 286 (38.4)
Educational level (years) Illiterate 13 (2.2) 1 (1.5) 3 (3.8) 17 (2.3)
1 – 5 139 (23.2) 15 (23.1) 26 (32.5) 180 (24.2)
6 – 11 228 (38) 22 (33.8) 32 (40.0) 282 (37.9)
412 220 (36.7) 27 (41.5) 19 (23.8) 266 (35.7)
Income (MWa) 0 – 2 88 (15.4) 9 (14.1) 23 (30.3) 120 (16.9)
2.1 – 5 198 (34.7) 22 (34.4) 27 (35.5) 247 (34.7)
45. 1 285 (49.9) 33 (51.6) 26 (35.2) 344 (48.4)
Comorbidities 0 – 1 248 (41.3) 35 (53.8) 18 (22.5) 301 (40.4)
2 – 3 286 (47.7) 26 (40.0) 48 (60.0) 360 (48.3)
44 66 (11.0) 4 (6.2) 14 (17.5) 84 (11.3)
IADLb Independent 298 (49.7) 35 (53.8) 19 (23.8) 352 (47.2)
Dependent 302 (50.3) 30 (46.2) 61 (76.3) 393 (52.8)
BADLc Independent 490 (81.7) 56 (86.2) 61 (76.3) 607 (81.5)
Dependent 110 (18.3) 9 (13.8) 19 (23.8) 138 (18.5)
Health self-perception Very Bad – Bad 30 (5.0) 0 (0.0) 6 (7.5) 36 (4.8)
Normal 234 (39.0) 24 (36.9) 32 (40.0) 290 (38.9)
Good - Very Good 336 (56.0) 41 (63.1) 42 (52.5) 419 (56.2)
Falls 0 432 (72.0) 51 (78.5) 52 (65.0) 535 (71.8)
1 – 2 141 (23.5) 12 (18.5) 21 (26.3) 174 (23.4)
X3 27 (4.5) 2 (3.1) 7 (8.8) 36 (4.8)
Total 600 (80.5) 65 (8.7) 80 (10.7) 745 (100)
aMinimum wage (2009-2010: U$ 265); there were 34 missing data points;
b Instrumental activities of daily living;
c Basic activities of daily living
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First, the wide variety of instruments used to identify MM,
muscle strength and physical performance may produce
differing values for these measures, which, in turn, may
affect the reported prevalence of sarcopenia (8). Second,
despite the growing evidence of their inadequacy (22) and
the strong recommendation for the development of norma-
tive data for each population (11), the cut-off points for GS
(0.8 m/s) and HS (20 kgf for women and 30 kgf for men)
have been extensively used to classify populations outside of
Northern Europe and North America, the regions in which
these values were originally defined. Therefore, the reported
sarcopenia prevalence rates may be inaccurate.
There are several examples of these issues mentioned
above. Recently, in a systematic review on sarcopenia
prevalence in Brazil, Diz et al. (23) found that of the 31
analyzed studies, 11 (35.5%) used all or some of the criteria
recommended by the EWGSOP, and the overall prevalence of
sarcopenia was 17%. Most of these studies used the cut-off
points for HS and GS proposed by EWGSOP, and the esti-
mated prevalence ranged from 4.1 to 65%. Consequently,
one should be careful of uncritically accepting these results.
There are many explanations for this huge variation in
prevalence. Most explanations involve biases introduced
during sample selection, the aforementioned use of different
tools, and the cut-off values chosen to determine HS and GS.
For example, the choice of cut-off points may explain the
high sarcopenia prevalence rates of 15.4%, 13.9%, and 21.8%
observed by Alexandre et al. (24), Barbosa-Silva et al. (25),
and Martinez et al. (26), respectively, in their studies of
community-dwelling and hospitalized older people in Brazil.
Table 3 - Sarcopenia prevalence estimated by the tailored and
EWGSOP cutoff points among community-dwelling individuals
aged 65 years or older who are residents of the northern region
of Rio de Janeiro, Brazil, 2010, stratified by sex. (n=745)
Male (n %) Female (n %) Total (n %)
Fibra-RJ Normal 177 (80.1) 421 (80.7) 598 (80.5)
Pre-sarcopenia 26 (11.8) 39 (7.5) 65 (8.7)
Sarcopenia 12 (5.4) 39 (7.5) 51 (6.9)
Severe
sarcopenia
6 (2.7) 23 (4.4) 29 (3.9)
EWGSOP Normal 177 (80.1) 421 (80.7) 598 (80.5)
Pre-sarcopenia 9 (4.1) 2 (0.4) 11 (1.5)
Sarcopenia 20 (9.0) 42 (8.0) 62 (8.3)
Severe
sarcopenia
15 (6.8) 57 (10.9) 72 (9.7)
po0.001
Table 4 - Sarcopenia and associated factors among individuals aged 65 years or older who are residents of the northern region of Rio
de Janeiro, Brazil, 2010. (N=680a)
Independent variables Categories Univariate Multivariate
OR (95% CI) p-value OR (95% CI) p-value
Sex Male 1 1
Female 1.4 (0.8-2.50) 0.19 0.63 (0.29-1.36) 0.24
Race Other 1 1 1
Caucasian 1.7 (1.02-2.85) 0.03 1.89 (1.02-3.52) 0.04
Age group (years) 65-74 1 1 1
75-84 9.67 (3.75-24.92) o0.001 9.72 (3.62-26.12) 0.000
485 42.9 (16.0-114.5) o0.001 37.2 (12.35-112.48) 0.000
Marital status Married/living with partner 1 1
Divorced/separated 2.1 (0.74-5.70) 0.09 1.98 (0.58-6.72) 0.27
Single 3.89 (1.70-8.50) o0.001 6 (2.20-16.39) 0.000
Widower 3.63 (2.0-6.61) o0.001 2.49 (1.15-5.37) 0.02
Educational level (years) 412 1 1
Illiterate 2.67 (0.70-10.20) 0.15 0.48 (0.09-2.60) 0.4
1-5 2.16 (1.15-4.0) 0.01 0.45 (1.18-1.12) 0.08
6-11 1.62 (0.89-2.95) 0.09 1.39 (0.65-2.95) 0.39
Income (MWb) 45. 1 1 1
0-2 2.86 (0.21-0.62) o0.001 3.64 (1.58-8.39) 0.002
2. 1-5 1.94 (0.84-2.63) 0.16 2.44 (1.20-4.94) 0.013
Comorbidities 0-1 1 1
2-3 2.31 (1.31-4) 0.004 2.55 (1.28-5.08) 0.008
44 2.9 (1.38-6.1) 0.005 3.26 (1.28-8.30) 0.013
IADLd Independent 1 1
Dependent 3.1 (1.84-5.43) o0.001 1.64 (0.86-3.11) 0.13
BADLd Independent
Dependent 1.38 (0.79-2.41) 0.24 - -
Health self-perception Good-Very Good
Very Bad-Bad 1.6 (0.62-4.0) 0.32 - -
Regular 1 (0.67-1.78) 0.70 - -
Falls 0 1
1-2 1.23 (0.72-2.10) 0.44 - -
X3 2.1 (0.89-5.10) 0.87 - -
Caloric expendituree First quintile 1.1 (0.65-2.0) 0.60 - -
a 65 individuals (pre-sarcopenic) were excluded;
bMinimum wage (2009-2010: U$ 265);
c Instrumental activities of daily living;
d Basic activities of daily living.);
e Caloric expenditure calculated by Minnesota Leisure Time Activities.
Hosmer-Lemeshow (0.84)
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Some studies have proposed normative data for muscle
strength and MM in the Brazilian population. Regarding the
cut-off points for palmar grip strength, Budziareck et al.
analyzed a convenience sample composed of 300 indivi-
duals from a city in the southern region of the country (27).
The sample consisted of individuals with a mean age of
44.9 years (SD 18.5). In another study, Schlussel et al.
presented the distribution of handgrip values by percentile
but did not report some values that are usually reported,
including the quartile and quintile values (28). Further-
more, the sample was composed of a small number of older
people organized in only two age groups (60-69 years and
X70 years).
Regarding the normative values for muscle mass, Barbosa-
Silva et al. suggested cut-off values for MM in their study
using DXA and calf circumference (CC) (25). The use of
DEXA is standard. However, CC has a weak correlation with
DXA, as shown in the systematic review published by
Mijnarends et al., (29). For this reason, CC appears to be a
poor proxy for MM.
The potential problems with cut-off values are not limited
to Brazilian research. Studies from other Latin American and
Asian countries have also adopted the cut-off points sug-
gested by the EWGSOP screening algorithm (11). For example,
Arango-Lopera et al. analyzed a community sample of 345
individuals over 70 years in Mexico City and found a pre-
valence of sarcopenia of 33.6% (30). Similarly, high sarcopenia
prevalence rates were observed in the studies by Wu et al.
(31) in Taiwan (12.8%) and by Yalcin et al. (32) in Turkey
(29%). Indeed, it is important to reiterate that using the same
cut-off values for populations with different genotypic and
phenotypic characteristics may yield unreliable results, thus
overestimating or underestimating the true prevalence (22).
Another strategy to define sarcopenia that is often used by
the researchers is to accept the universality of the GS cut-off
value of p0.8 m/s as a reference for slow walking. It was
first proposed by Lauretani et al. and was recently proposed
again by The Foundation of National Institute of Health
Sarcopenia Project (FNIH) (33). The FNIH collected pooled
data from multiple studies to develop criteria for weakness
and low MM based on the association of both variables with
slow GS (34). The FNIH found HS cut-off points of p16 kgf
and 26 kgf and sarcopenia prevalence rates of 1.3% and 2.3%
for women and men, respectively. Souza Barbosa et al. used
the same strategy to estimate the prevalence of slow GS and
weakness in a sample of elderly people from high- and
middle-income countries (35). The maximum values of grip
strength were 41.68 and 31.88 kgf in Canada and Brazil,
respectively. The associated prevalences of weakness were
3.9 and 14.8%, respectively. This difference is probably a
consequence of the cut-off points for GS that were used to
determine a slow pace (GSp0.8 m/s) in these distinct popu-
lations. These results support Lourenc¸o et al.’s report (22)
that suggests that the clinically relevant reference value for
GS in Latin America may be different from 0.8 m/s, and
the use of this value to classify slow GS in older people may
result in bias.
Additionally, Bahat et al. attempted to improve the general
applicability of the sarcopenia criteria in Turkey by suggest-
ing cut-off values for MM, HS, and CC (12). They studied
two non-random samples composed of young and elderly
adults and assessed MM using BIA, HS by its association
Figure 1 - Venn diagram displaying the percentage of subjects [% (n)] who had low muscle mass and/or low handgrip strength and/or
low gait speed amongst 745 individuals aged 65 years or older who are residents of the northern region of Rio de Janeiro, Brazil, 2010.
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with a slow pace(GS o0.8 m/s), and CC by identifying
participants with MMo9.2 kg/m2 for men ando7.4 kg/m2
for women. They concluded that the cut-off thresholds for
MM, HS, and CC were higher in Turkey than in other
reference populations. However, their results may have been
biased due to their acceptance of the universality of the GS
cut-off value, the use of BIA as a reference for CC, and the
unreliable use of CC as a measure of MM.
In addition, it is worth mentioning two other studies that
suggest differences in HS reference values across different
regions. Dodds et al. performed a meta-analysis highlighting
the use of the British HS reference values in consensus
definitions for sarcopenia across developed regions (36).
However, they emphasized the need for different cut-off
values in developing regions. Leong et al. analyzed the range
of HS values in 125,462 healthy adults in 21 countries and
highlighted the differences in HS among people from
different geographic regions (Asia, Europe, Africa, and the
Americas) (37). They strongly suggested that individual HS
measurements should be interpreted using region/ethnic-
specific reference ranges.
In addition to cut-off points for each population, other
determinants of sarcopenia should be considered, including
age, gender, geography, and individual risk factors (38). The
methods used to define cut-off values may be directly
influenced by these determinants. This is a concern for HS
classification using BMI, which was the strategy used in the
present study. Notwithstanding the fact that Budzireck et al.
(27) did not find a correlation between BMI and HS, there
have been several studies supporting this approach (15).
Although they used cut-off values from another popula-
tion, Alexandre et al. (24) identified in a Brazilian population
that age and income were also risk factors for sarcopenia, as
observed in the present study. The first is well established in
the literature (38). However, income and other sociodemo-
graphic variables need to be further studied, especially in
developing countries.
There were some limitations in the present study. The use
of anthropometric equations capable of predicting MM are
practical and simple methods that are convenient in low
income countries (11,39). However, the accuracy of this
method is not ideal. Another issue is that the formula used
for the estimation of MM in the present study calculated the
total skeletal MM. Some investigators suggest that appendi-
cular MM should be used (8). Therefore, there is a possibility
that the sarcopenia prevalence determined in the present
study was an underestimate.
The sample in the present study was obtained from a
health care provider, with different sociodemographic data,
income levels and educational levels, and the results should
not be generalized. On the other hand, 25% of those using the
Brazilian health system are supported by the Supplementary
Health Care System (a total of 50 million individuals and 7
million over 60 years); therefore, it is very important to know
the health status of this population subgroup (40).
’ CONCLUSION
Previous studies have indicated that the prevalence of
sarcopenia varies greatly depending on the MM, HS and GS
cut-off values employed to estimate it. In the present study,
the prevalence rates of sarcopenia and its associated factors
were similar to those reported in other studies once the MM,
HS and GS values were tailored for the specific populations
and adopted as the diagnostic criteria.
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